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Cytochrome c oxidaseThe loss of Surf1 protein leads to a severe COX deﬁciencymanifested as a fatal neurodegenerative disorder, the
Leigh syndrome (LSCOX). Surf1 appears to be involved in the early step of COX assembly but its function re-
mains unknown. The aim of the study was to ﬁnd out how SURF1 gene mutations inﬂuence expression of
OXPHOS and other pro-mitochondrial genes and to further characterize the altered COX assembly. Analysis
of ﬁbroblast cell lines from 9 patients with SURF1mutations revealed a 70% decrease of the COX complex con-
tent to be associated with 32–54% upregulation of respiratory chain complexes I, III and V and accumulation of
Cox5a subunit. Whole genome expression proﬁling showed a general decrease of transcriptional activity in
LSCOX cells and indicated that the adaptive changes in OXPHOS complexes are due to a posttranscriptional
compensatory mechanism. Electrophoretic and WB analysis showed that in mitochondria of LSCOX cells com-
pared to controls, the assembled COX is present entirely in a supercomplex form, as I–III2–IV supercomplex
but not as larger supercomplexes. The lack of COX also caused an accumulation of I–III2 supercomplex. The ac-
cumulated Cox5a was mainly present as a free subunit. We have found out that the major COX assembly sub-
complexes accumulated due to SURF1mutations range in size between approximately 85–140 kDa. In addition
to the originally proposed S2 intermediate they might also represent Cox1-containing complexes lacking other
COX subunits. Unlike the assembled COX, subcomplexes are unable to associate with complexes I and III.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The eukaryotic cytochrome c oxidase (COX) (E.C.1.9.3.1), the com-
plex IV (cIV) of the mitochondrial respiratory chain, is a multimeric
enzyme of dual genetic origin, whose assembly is a complicated and
highly regulated process.
The COX monomer of 205 kDa consists of 13 subunits. The three
largest subunits Cox1, Cox2 and Cox3 are highly hydrophobic trans-
membrane proteins encoded by mitochondrial DNA and form the cat-
alytic core. The ten small subunits (Cox4, Cox5a, Cox5b, Cox6a, Cox6b,
Cox6c, Cox7a, Cox7b, Cox7c and Cox8) surrounding the core of the
enzyme are encoded in the nuclear genome. They are necessary for
the regulation of the COX functioning [1,2], the assembly/stability of
the holoenzyme and for COX dimerization. Nijtmans et al. proposed
a model showing four assembly intermediates (S1–S4) that accumu-
late during COX assembly [3]. Cox1 represents the ﬁrst intermediate; COX, cytochrome c oxidase;
oxidase deﬁciency; cI, cII, cIII,
l ATP synthase
: +420 2 4106 2149.
.
l rights reserved.S1 which proceeds to Cox1–Cox4–Cox5a subassembly by insertion
of Cox4–Cox5a heterodimer. The Cox2 then supposedly joins this S2
intermediate. The process continues by the formation of the third
proposed intermediate S3 by the addition of most of the remaining
subunits. Finally, Cox6a and Cox7a/b are added to complete the holo-
enzyme [3–5]. The incorporation of small, nuclear encoded subunits
in the late stages of COX assembly has been addressed by recent stud-
ies [6,7] that indicate the existence of additional assembly intermedi-
ates as well as possible incorporation of some of these subunits into
already preexisting holoenzyme, similarly as found in complex I bio-
genesis [8].
The COX assembly is a multistep progression through discrete
short-lived intermediates requiring more than 30 diverse assistant
factors. Of them, Surf1 is most likely involved in an early step of as-
sembly during the association of Cox2 subunit with Cox1–Cox4–
Cox5a subassembly. There is also evidence that Surf1 may act in the
formation of heme a3-CuB center [9]. Other known assembly proteins
such as Sco1, Sco2, Cox11 and Cox17 are necessary for the copper in-
sertion into COX. Proteins encoded by genes COX10 and COX15 are in-
volved in the heme a biosynthesis [5,10].
COX deﬁciencies are mainly COX assembly defects. There are two
main groups of COX defects that are caused by mutations either in
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ar genes encoding assembly factors. Recently, the ﬁrst mutation in a
nuclear-encoded structural subunit Cox6b1 was reported which
causes a mitochondrial encephalomyopathy [11].
Up to now, pathogenic mutations in several assembly factors have
been described. Quite common are mutations in SCO1, SCO2 [12],
COX10 [13] and COX15 [14] but the most frequent are mutations in
SURF1 gene [10]. Human Surf1 is a 30 kDa transmembrane protein lo-
calized in the inner mitochondrial membrane [4,9]. The loss of the
human Surf1 function is associated with Leigh syndrome, a fatal neuro-
degenerative disorder caused by severe COX deﬁciency (LSCOX). Leigh
syndrome is frequent, although genetically heterogeneous, mitochon-
drial disorder [15,16]. It manifests as a progressive encephalopathy,
mainly characterized by bilateral necrotic lesions in the basal ganglia
and brainstem [17,18]. The ﬁrst symptoms usually appear before two
years of age and consist of optic atrophy, ophthalmoparesis, hypotonia,
ataxia and dystonia. Most patients die a few years after the onset of
symptoms [19,20].
In this work we focused on a further characterization of the isolat-
ed COX deﬁciency due to mutations in SURF1 gene. The exact function
of this protein is still unknown but it was suggested that human Surf1
promotes the association of Cox2 with the assembly intermediate
composed of Cox1, Cox4 and Cox5a. The aim of the present study
was to ﬁnd out how mutations in SURF1 gene inﬂuence protein and/
or transcript level of OXPHOS and other pro-mitochondrial genes
and to further characterize the altered COX assembly. In the experi-
ments we used ﬁbroblasts from 9 patients carrying different muta-
tions in SURF1 gene (Table 1) and 5 control ﬁbroblast cell lines.
Our results indicate that SURF1 gene mutations induce a pro-
nounced, but variable decrease in the protein content of COX subunits
apparent as relative enrichments in Cox5a subunit, but also a com-
pensatory increase in respiratory complexes I, III and V, not mirrored
by any changes in transcript levels for subunits of OXPHOS complexes
and related mitochondrial biogenesis factors. A detailed analysis of
COX assembly process shows that the patient ﬁbroblasts accumulate
the Cox5a subunit and assembly intermediates between ~85 and
140 kDa containing dominant portion of Cox1 but only substoichio-
metric amounts of Cox4-1, Cox5a or Cox2, and that assembled COX
in LSCOX ﬁbroblasts is exclusively present in a supercomplex form.
2. Material and methods
2.1. Patients
Fibroblast cell lines from 9 patients with SURF1 mutations and
COX deﬁciency were used in this study. All the patients showed
major clinical symptoms associated with mitochondrial disease due
to COX speciﬁc defect. For relevant clinical, biochemical and molecu-
lar data on individual patients see [20,21] and Table 1. Importantly,
Western blot experiments conﬁrmed the absence of Surf1 protein inTable 1
SURF1 mutations in LSCOX ﬁbroblasts used in the study.
Patient Exon Mutations Mutation type
P1 9/7 845 del CT/T704>C Frameshift: stop codon 870–872/
Met235>Thr
P2 9/9 845 del CT/845 del CT Frameshift: stop codon 870–872
P3 9/? 845 del CT/? Frameshift: stop codon 870–872/?
P4 9/8 845 del CT/A821>G Frameshift: stop codon 870–872/
Tyr274>Cys
P5 9/9 845 del CT/845 del CT Frameshift: stop codon 870–872
P6 9/? 845 del CT/? Frameshift: stop codon 870–872/?
P7 6/9 C574>T/845 del CT Arg192>Trp/Frameshift: stop codon
870–872
P8 4/8–9 312 insATdel10/821 del18 Frameshift: stop codon 316–318/exon
8 removal
P9 7/7 C688>T/C688>T Arg230>stopall patient cell lines used in this study [20,21]. Selected 5 control ﬁ-
broblast cell lines were used repeatedly in previous diagnostic bio-
chemical tests and showed no signs of any mitochondrial or other
metabolic defect.
The project was approved by the ethics committees of all collabo-
rating institutions. Informed consent was obtained from the parents
of the patients according to the Declaration of Helsinki of the World
Medical Association.
2.2. Cell cultures
Human skin ﬁbroblasts were cultured at 37 °C in 5% CO2 atmo-
sphere in the DMEM medium (with L-glutamine, sodium pyruvate
and high glucose concentration 4.5 g/l) supplemented with 10%
fetal bovine serum, 20 mM HEPES pH 7.5 and in the presence of pen-
icillin (10 U/ml) and streptomycin (10 μg/ml). Cells were harvested
using 0.05% trypsin and 0.02% EDTA and washed twice in
phosphate-buffered saline (PBS, 140 mM NaCl, 5 mM KCl, 8 mM
Na2HPO4, 1.5 mM KH2PO4, pH 7.2).
2.3. Isolation of mitochondria
Isolation utilizing hypotonic disruption of cells was carried out
according to [22] with slight modiﬁcations to increase the yield.
Weighed cell pellet was suspended in ten times the amount of
10 mM Tris-buffer supplemented with protease inhibitor cocktail
(PIC, Sigma, 1:500). Cells were homogenized using Teﬂon/glass ho-
mogenizer (8 strokes, 600 rpm) and immediately 1/5 volume of
1.5 M sucrose was added. Homogenate was centrifuged at 600 g,
10 min at 4 °C and supernatant was saved. The pellet was suspended
in the original volume of SEKTP (250 mM sucrose, 40 mM KCl, 20 mM
Tris, 2 mM EGTA, pH 7.6, PIC 1:500), rehomogenized and centrifuged
again at 600 g. Pooled supernatants were centrifuged at 10000 g,
10 min at 4 °C min and pelleted mitochondria were washed by centri-
fugation and suspended in SEKTP. Protein concentration was mea-
sured by Bradford method (BioRad).
2.4. Isolation of membranes
For native electrophoresis, mitochondria-enriched membrane
fraction was prepared from 20 mg wet weight aliquots of sedimented
cells as described [23]. Brieﬂy, cells were homogenized (30 strokes,
500 rpm) in 0.5 ml of 83 mM sucrose, 6.6 mM Imidazole pH 7, PIC
1:500, and centrifuged at 20000 g, 10 min at 4 °C. Samples were fro-
zen and stored at −80 °C.
2.5. Electrophoretic techniques and immunoblotting
Samples of mitochondria or pelleted cell membranes were solubi-
lized for 15 min at 0 °C using indicated concentrations of dodecyl
maltoside or digitonin and centrifuged for 20 min at 20000 g. Pro-
teins in supernatants were analyzed by BN-PAGE and hrCN3-PAGE
[23,24] on 6–15% separating gel using the Mini-Protean apparatus
(BioRad). For two-dimensional electrophoresis, gel slices from the
1st dimension were incubated in 1% SDS and 1% mercaptoethanol
for 1 h and then subjected to SDS-PAGE on 10% slab gels [25].
Proteinswere transferred fromgels to PVDF-membranes (Immobilon-
P, Millipore) using semidry electrotransfer. The membranes were
blocked with 10% non-fat dried milk in TBS (150 mM NaCl, 10 mM
Tris, pH 7.5) for 1 h and incubated for 2 hwith the speciﬁc primary an-
tibodies diluted in TBST (TBS with 0.1% Tween-20). Monoclonal anti-
bodies to NDUFB6, Core1, Rieske protein, Cox1, Cox2, Cox4-isoform 1,
Cox5a, d subunit of cV and Blue Native OXPHOS Complexes Detection
Kit (containing monoclonal antibodies to NDUFA9, SDH 70, Core2,
Cox4, α-subunit of complex V) were obtained from Mitosciences; goat
polyclonal antibody to Cox3 was from Santa Cruz Biotechnology; rabbit
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mGPDH was custom prepared against the C-terminal of the protein
[27]; and rabbit antibody to porin (VDAC1) was a kind gift from Prof.
Vito De Pinto, University of Catania. Membranes were then incubated
for 1 h with corresponding secondary ﬂuorescent antibodies — IRDye
680- or 800-conjugated donkey anti-goat IgG or goat anti-mouse IgG
(Molecular Probes) or goat anti-rabbit IgG (Rockland). Detection of pro-
teins was performed using Odyssey ﬂuorescence scanner at the excita-
tion of 680 nmand emission of 700 nmor 800 nm. The quantiﬁcation of
signals was carried out in Aida Image Analyzer program version 3.21.
For presentation, the data from individual control and patient cell
lines were averaged and subgroups were statistically evaluated using
Student's t-test.
2.6. In-gel activity staining of complex IV
Activity staining of complex IV in native gels was performed
according to a modiﬁed protocol originally described in [28]. Gel
slices were stained using solution of 50 mM sodium phosphate buffer
(pH 7.4), 0.5 mM DAB (3,3′-diaminobenzidine tetrahydrochloride)
and 1.1 mM oxidized cytochrome c overnight. For better visibility of
reddish bends indicating complex IV activity in contrast to the Coo-
massie stain background, gels were scanned through blue ﬁlter.
2.7. RNA preparation, cDNA labeling and hybridization
Total RNA was isolated from patient and control cultured cells
using the TRIZOL solution (Invitrogen). As a common reference RNA
for gene expression studies, total RNA from cultured HeLa cells was
used. RNA concentration was determined spectrophotometrically at
260 nm by NanoDrop (NanoDrop Technologies) and its quality was
checked on Agilent 2100 bioanalyzer (Agilent Technologies). Aliquots
of isolated RNA were stored at −80 °C until the analysis.
Isolated RNA (500 ng) was reverse transcribed, labeled and
hybridized onto Agilent 44 k human genome microarray using Two-
color Microarray Based Gene Expression Analysis Kit (Agilent Tech-
nologies). All 9 patient and 5 control samples (Cy5-labeled) were hy-
bridized against common reference RNA (Cy3-labeled).
The hybridized slides were scanned with GenePix 4200A scanner
(Axon Instruments) with PMT gains adjusted to obtain unsaturated
images of the highest intensity. Agilent Feature Extraction software
was used for image analysis of the TIFF ﬁles, generated by the scanner.
2.8. Experimental setup and microarray data normalization
Comparative analysis was performed according to MIAME guide-
lines [29]. Normalization was performed in R statistical environment
(http://www.r-project.org) using the Limma package [30] which is
part of the Bioconductor project (http://www.bioconductor.org).
Raw data from individual arrays were processed using Loess normal-
ization and normexp background correction. The quantile function
was used for normalization between arrays. Linear model was ﬁtted
for each gene given a series of arrays using lmFit function. The empir-
ical Bayes method was used to rank differential expression of genes
using eBayes function. Multiple testing corrections were performed
using Benjamini and Hochberg method [31].
Data accession — gene expression data reported in this study are
stored and available in Gene Expression Omnibus repository (GEO
ID: GSE26322) and (GEO ID: GPL 4133).
2.9. Statistical analysis
Gene expression was assessed as described previously [32] and
gene expression signals were background corrected, log2 trans-
formed and normalized using the quantile normalization method.
Signiﬁcant gene expression changes between control and patientsubgroups were identiﬁed using t-test in R statistical environment
(http://www.r-project.org/). Applied parameters are provided in cor-
responding result sections.
3. Results
3.1. Compensatory upregulation of OXPHOS complexes
The ﬁrst aim of the study was to investigate whether the content
of respiratory chain complexes can be modiﬁed as a consequence of
SURF1 mutations. Our previous study [21] indicated an increased
content of F1-ATPase α subunit in LSCOX patients that pointed to a
compensatory mechanism induced by impaired energy provision.
Therefore, we used the whole cell homogenate and isolated mito-
chondria from ﬁbroblasts of LSCOX patients and controls to quantify
the content of OXPHOS protein complexes by Western blotting of
the proteins separated by SDS-PAGE. For immunodetection we used
the OXPHOS Complexes Detection Kit (Mitosciences) containing spe-
ciﬁc monoclonal antibodies to representative subunits of OXPHOS
complexes — NDUFA9 subunit of complex I, 70 kDa subunit of com-
plex II, Core2 subunit of complex III, Cox4 subunit of complex IV,
and alpha subunit of complex V. Their signals were related to the sig-
nal of the mitochondrial marker porin. Fig. 1A shows that the low
content of complex IV (cIV) was associated with a slight increase in
the content of complex I (cI), III (cIII) and V (cV) in LSCOX whole cell
lysates. This was even more apparent and signiﬁcant when analyzing
isolated mitochondria (Fig. 1B). Speciﬁcally, a 70% decrease in cIV
resulted in a 48% increase in the content of cI, 54% increase of cIII
and 32% increase of cV, indicative of compensatory changes triggered
by COX dysfunction and impairment of mitochondrial energy provi-
sion. Similar statistically signiﬁcant upregulation of OXPHOS complexes
content in LSCOX cells was observed using individual antibodies against
other subunits of complexes I, III, and V—NDUFB6 of cIwas increased to
147% of control (pb0.05), Core1 and Rieske protein of cIII were in-
creased to 149% and 170% of control, respectively (pb0.01 and
pb0.05, respectively), d and a subunits of cV were upregulated to
118% and 126% of control, respectively (pb0.05 and pb0.01, respective-
ly). In contrast, the amounts of other dehydrogenases of the respiratory
chain, complex II (cII) and mitochondrial glycerol 3-phosphate dehy-
drogenase (mGPDH) were not changed.
3.2. Variable content of COX subunits
As COX deﬁciency due to the absence of Surf1 assembly factor is
characterized by accumulation of incomplete COX assemblies, we
also determined the amount of several COX subunits in LSCOX ﬁbro-
blasts in order to uncover putative variations in subunit content
reﬂecting the impaired assembly. Control and LSCOX samples were an-
alyzed by SDS-PAGE and Western blotting using monoclonal anti-
bodies to three mitochondrial encoded COX subunits — Cox1, Cox2
and Cox3, and to two nuclear encoded COX subunits — Cox4 and
Cox5a, all of which are implicated in early stages of COX assembly.
Their content was again related to the content of porin. Both in ho-
mogenates and isolated mitochondria, all tested COX subunits
showed a pronounced, but variable decrease in LSCOX ﬁbroblasts.
The decrease of individual subunits was 40–78% in cell homogenates
(Fig. 2A) and 39–86% in isolated mitochondria (Fig. 2B). In both cases,
the least decreased of the ﬁve tested subunits was the subunit Cox5a,
indicating its relative accumulation compared to other COX subunits.
3.3. Gene expression proﬁle and its correlation with protein content
To ﬁnd out how the isolated COX deﬁciency modulates the expres-
sion of genes in LSCOX ﬁbroblasts at the transcriptional level, whole
genome transcript levels were determined in LSCOX and control ﬁbro-
blasts using the 44 k human cDNA Agilent microarray.
Fig. 1. Changes in the content of respiratory chain complexes in LSCOX ﬁbroblasts. Western blot analysis of homogenates (A) and isolated mitochondria (B) from ﬁbroblasts of pa-
tients (P) and controls (C) was performed using antibodies to subunits of cI (NDUFA9), cII (70 kDa subunit), cIII (Core2), cIV (Cox4-1), cV (alpha subunit), and mGPDH. Detected
signals were quantiﬁed separately for individual control and patient cell line and related to the signal of mitochondrial porin detected from the same blots. All data of controls and
patients were averaged and obtained value for patients was expressed as a percentage of controls value. Values are mean±SE of 3 experiments, pb0.05 (*), pb0.01 (**).
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patient subgroups indicated upregulation of 18501 genes (42%) and
downregulation of 24832 genes (56%), but signiﬁcant changes were
shown only in a small number of genes (Table 2). Thus, 507 genes
were differentially expressed at pb0.05 value and 95 genes at
pb0.01. In case of genes encoding OXPHOS structural subunits, 20
were changed at pb0.05 (11 subunits of cI, 1 subunit of cIII, 2 subunit
of cIV and 6 subunits of cV), but all of them were less expressed in
LSCOX compared to controls, in contrast with the protein analysis. Of
them, 3 genes have been 1.7–2 fold downregulated at pb0.01, namely
cI subunits NDUFA4 and NDUFB6 and cV inhibitor protein IF1. In addi-
tion, the expression of intramitochondrial superoxide dismutase
(SOD1) was also decreased two-fold at pb0.001.
The increased content of respiratory chain cI, cIII and cV observed
at the protein level was thus apparently not due to transcriptional
upregulation of structural subunits genes. It is also important that
no indication could be observed that the increase in these complexes
could be ascribed to a signiﬁcant upregulation of different regulatory
genes. There was neither a signiﬁcant change in the expression of
genes encoding speciﬁc ancillary or assembly factors of the respirato-
ry chain complexes, nor in mitochondrial biogenesis regulatory
genes, such as PGC1A, NRF1 or TFAM. The compensatory OXPHOS
upregulation in LSCOX ﬁbroblasts must therefore arise at later stages
of protein expression.
Only the downregulation of mRNAs for two small, nuclear encoded
COX subunits Cox7a2 and Cox6c (Table 3) seems to correspond to thedecrease of COX complex. However, considering that the content of
COX subunits is decreased due to the stalled assembly, the transcrip-
tional downregulation of these two subunits may only be coincidental
since they are incorporated into the COX complex at the late stage of
the assembly process.
3.4. Modiﬁed COX assembly pattern in LSCOX ﬁbroblasts
While it has long been established that Surf1 deﬁciency is associ-
ated with a pronounced COX deﬁciency and accumulation of its as-
sembly intermediates, most studies to date have been using
relatively strong detergent dodecyl maltoside to analyze the assembly
pattern of cytochrome c oxidase by BN-PAGE. In order to identify COX
assemblies under conditions closer to the in-situ state, we solubilized
isolated membrane fractions from LSCOX and control ﬁbroblasts with
the mild detergent digitonin (4 and 8 g/g protein) and separated
them using native electrophoretic techniques BN-PAGE and hrCN3-
PAGE, which allow for detection of native OXPHOS supercomplexes.
In control ﬁbroblasts, the signal from antibodies against Cox1,
Cox4-1 and Cox5a (Fig. 3A–C) was distributed among the i) COX
monomer, ii) COX dimer and heterodimers and iii) supercomplexes
(relative content of i/ii/iii approximately 1:0.25:1 — see quantiﬁca-
tion or distribution proﬁles in Fig. 3). The supercomplexes' migration
distance and parallel WB detection with antibodies raised against
subunits of cI and cIII (NDUFB6 and Core1, respectively) (Fig. 3D), in-
dicated that the detected supercomplexes represent the previously
Fig. 2. Decreased content of COX subunits in LSCOX ﬁbroblasts. Homogenates (A) and isolated mitochondria (B) from ﬁbroblasts of patients (P) and controls (C) were analyzed by
Western blots using antibodies to COX subunits 1, 2, 3, 4-1 and 5a. Signals were processed as described in Fig. 1. Values are mean±SE of 3 experiment, pb0.01 (**).
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(supercomplexes consisting of one copy of complex I, dimer of com-
plex III, and 1–3 copies of complex IV), the ﬁrst one being the most
abundant. Interestingly, the vast majority of the cI and cIII signals
were found in supercomplexes, in contrast with cIV, which seems to
reﬂect the excess capacity of COX. A strikingly different pattern was
observed in LSCOX ﬁbroblasts. Here, the signal from anti-COX anti-
bodies was mainly distributed between an assembly intermediate of
about 130 kDa and a single form of supercomplex. Very little of COX
monomer and almost no dimer could be detected in patient cells
(Fig. 3A–C) as apparent from the relative content of these assemblies
(note that the three-fold amount of patient sample relative to control
was used). Based on the comparison with the control lane, the single
supercomplex in LSCOX represents the I1–III2–IV1 species. The detec-
tion of the I1–III2 supercomplex and the dimer of cIII in patient ﬁbro-
blasts (Fig. 3D) indicates that the low content of COX limits the
supercomplex assembly. The absence of larger supercomplexes mayTable 2
Differentially expressed genes in LSCOX ﬁbroblasts.
Genes p value Changed Down Up
All 0.05 507 347 160
0.01 95 72 23
OXPHOS 0.05 20 20 0
0.01 3 3 0indicate that the association of multiple copies of cIV is less stable
than the “core” I1–III2–IV1 species, and therefore requires more abun-
dant pool of COX than in control ﬁbroblasts. Alternatively, the assem-
bly of COX in the absence of Surf1 may yield complexes with slightly
modiﬁed structure preventing their multimerization.
An apparently identical migration distance of the I1–III2–IV1 spe-
cies in control and LSCOX cells as well as its detection with all of the
used antibodies suggest that this supercomplex contains the fully as-
sembled COX in patient ﬁbroblasts. This was conﬁrmed by COX in-gel
activity staining, which detected active COX as a monomer and also in
the supercomplex region in both control and patient sample (Fig. 3C).
Indeed, in a parallel BN-PAGE experiment with dodecyl maltoside-
solubilized membrane fractions, we observed dissociation of the
COX-containing supercomplex with a simultaneous increase in the
content of COX holoenzyme in both the control and LSCOX ﬁbroblasts
(Fig. 4). To provide further evidence, we performed two-dimensional
BN/BN-PAGE analysis of the supercomplex composition (Fig. 5).
While the BN-PAGE in the ﬁrst dimension preserves the supercom-
plex associations in digitonin-solubilized samples, the presence of
dodecyl maltoside in the cathode buffers of the second dimension
BN-PAGE results in their dissociation into free complexes. Western
blot detection with Cox1 and Cox4 antibodies revealed a dominant
form of COX dissociating from the supercomplexes in both the control
and patient cells with approximate size of 200 kDa, apparently repre-
senting the fully assembled COX holoenzyme (Fig. 5). The other, less
dominant bands below the monomer recognized by both Cox1 and
Cox4-1 antibodies represented dissociation products of COX likely
Table 3
Differential expression of OXPHOS genes in LSCOX ﬁbroblasts at pb0.05.




SOD1 Superoxide dismutase 1 −1.03 2.00 0.001
NDUFA4 NADH dehydrogenase, 1 alpha subcomplex,
subunit 4, 9 kDa
−0.97 2.00 0.002
NDUFB6 NADH dehydrogenase, 1 beta subcomplex,
subunit 6, 17 kDa, t.v. 2
−0.80 1.70 0.008
ATPIF1 ATP synthase, inhibitory factor 1, t.v. 3 −0.73 1.66 0.01
ATP5H ATP synthase, subunit d, t.v. 1 −0.71 1.60 0.02
COX6C Cytochrome c oxidase, subunit 6c −0.84 1.80 0.02
NDUFAF2 NADH dehydrogenase, 1 alpha subcomplex,
assembly factor 2
−0.72 1.70 0.02
ATP5J2 ATP synthase, subunit F2, t.v. 1 −0.69 1.60 0.02
NDUFA12 NADH dehydrogenase, 1 alpha subcomplex,
subunit 12, 13 kDa
−0.81 1.70 0.02
NDUFA1 NADH dehydrogenase, 1 alpha subcomplex,
subunit 1, 7.5 kDa
−0.72 1.70 0.03
NDUFA2 NADH dehydrogenase, 1 alpha subcomplex,
subunit 2, 8 kDa
−0.70 1.60 0.03
NDUFB3 NADH dehydrogenase, 1 beta subcomplex,
subunit 3, 12 kDa
−0.65 1.60 0.03
ATP5J ATP synthase, subunit F6 −0.70 1.60 0.03
ATP5C1 ATP synthase, gamma subunit, t.v. 2 −0.61 1.50 0.04
NDUFB10 NADH dehydrogenase, 1 beta subcomplex,
subunit 10, 22 kDa
−0.59 1.50 0.04
COX7A2 Cytochrome c oxidase subunit 7a
polypeptide 2 (liver)
−0.64 1.60 0.04
NDUFA8 NADH dehydrogenase, 1 alpha subcomplex,
subunit 8, 19 kDa
−0.63 1.50 0.04
NDUFA6 NADH dehydrogenase, 1 alpha subcomplex,
subunit 6, 14 kDa
−0.59 1.50 0.05
UQCRQ Ubiquinol-cytochrome c reductase, subunit
VII, 9.5 kDa
−0.60 1.50 0.05
ATP5E ATP synthase, epsilon subunit −0.66 1.60 0.05
NDUFS7 NADH dehydrogenase, Fe–S protein 7,
20 kDa
−0.56 1.50 0.05
t.v. — transcription variant.
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experiment, as they migrate in direct vertical below the monomer.
3.5. Accumulation of non-canonical assembly intermediate in LSCOX
ﬁbroblasts
As expected, the analysis of COX subunits in Fig. 2 revealed a de-
creased content of several detected COX subunits in a LSCOX patient
but it also suggested that Cox5a is much less affected in case of
Surf1 defect compared with other subunits. To ﬁnd out in which
form this subunit accumulates we performed a detailed analysis of
COX assembly intermediates and subcomplexes solubilized from mi-
tochondrial membranes by mild detergent digitonin, using antibodies
to Cox5a, Cox4-1, Cox2 and Cox1 subunits. When a two-dimensional
BN/SDS-PAGE was performed to resolve well the low molecular
weight region, a distinct distribution of COX subunits 1, 2, 4 and 5a
was apparent (Fig. 6A). The second dimension yielded resolution su-
perior to the BN gel that allowed for an easier identiﬁcation of early
assembly intermediates of subunits 4 and 5a. In the LSCOX cells,
Cox5a was present mainly as a free subunit (band y), less in COX ho-
loenzyme, Cox4–Cox5a complex (band x) or in supercomplexes. The
Cox4 was also present in LSCOX cells in free form (band z) and as as-
sembly subcomplexes, but most of Cox4 was detected in holoenzyme
and supercomplexes. The Cox1was present in LSCOX cells in supercom-
plex, COX monomer and dominantly in the detected subcomplex, to-
gether with Cox4 and Cox5a. This major subcomplex accumulating in
patient ﬁbroblast with SURF1 mutations was repeatedly considered as
the S2 assembly intermediate. However, its size detected in our immu-
nodetection experiments (~130 kDa broad band ranging ~85–140 kDa)
only marginally corresponds to the theoretical mass of the Cox1–Cox4–Cox5a complex (85 kDa). Although the mass determination may be
misleading due to speciﬁc detergent micelles behavior, the migration
range and shape of the band of the anti Cox1 antibody suggests at
least two major entities being present (Fig. 6B), with the smaller align-
ing with a Cox1-containing subassembly present marginally also in the
control cells. Furthermore, from the 2D Western blot images it became
clearly apparent that Cox4 and Cox5a are present in substoichiometric
amounts in this subcomplex (Fig. 6A). When the COX holoenzyme,
with the assumed 1:1:1 ratio of the subunits, was used as a reference
for relative quantiﬁcation, the proportion of Cox1 appeared to be in pro-
nounced excess over the Cox4 and Cox5a subunits. Parallel quantiﬁca-
tion directly from the ﬁrst dimension BN gels yielded similar subunit
ratios, although in this case the quantiﬁcation is less reliable due to pos-
sible problems with antibody reactivity towards native proteins within
detergentmicelles. Both systems, however, indicated underrepresenta-
tion of the nuclear-encoded subunits in the putatively stoichiometric
Cox1–Cox4–Cox5a subassembly. Therefore, we hypothesize that the
detected band could represent a so far incompletely characterized com-
plex, or rather comigrating complexes that may include the S2 interme-
diate as well as other protein factors involved in COX assembly. The
signal of Cox2 was present in COX monomer and supercomplex but a
small amount of Cox2was also in the 130 kDa region, again strongly un-
derrepresented with respect to Cox1.
To provide a comparison of our ﬁndings using digitonin solubili-
sates with previous studies where COX assembly was analyzed by
2D BN/SDS PAGE in samples solubilized by dodecyl maltoside, we
performed a parallel experiment using this stronger detergent. As
expected, the majority of signal found in the supercomplexes region
shifted towards the COX monomer (Fig. 6C). The migration of the
subcomplexes shifted towards lower molecular weights, creating pat-
tern similar to studies that identiﬁed the S2 and S1 intermediates in
the LSCOX cells (Fig. 6C, D). Whether the migration difference of as-
sembly intermediates, solubilized by either digitonin or dodecyl mal-
toside, is solely due to different detergent micelles or rather due to
partial dissociation of Cox1-containing subcomplex using stronger
detergent could not be deﬁnitively judged in this experimental
setup. Nevertheless, the underrepresentation of Cox4 and Cox5a ver-
sus Cox1 (relatively as compared to the antibody signal ratios in the
holoenzyme) is retained in experiments using both detergents.
4. Discussion
Mitochondrial disorders due to impaired structure and function of
the OXPHOS system can be associated with upregulation of mito-
chondrial biogenesis and increased mitochondrial content, or subcel-
lular distribution such as in RRFs [33] or in myocardial tissue from
failing heart [34]. The mechanism underlying these changes is, how-
ever, unclear.
In this study we investigated whether the frequent type of COX
deﬁciency due to SURF1mutations can also be followed by compensa-
tory changes in the OXPHOS system and found apparent upregulation
of three respiratory chain complexes — cI, cIII and cV. Rather than di-
rect consequence of the Surf1 protein absence, we hypothesize that
the compensatory upregulation is triggered by secondary effects of
the energy provision impairment due to COX deﬁciency. One of the
triggers might be decreased mitochondrial membrane potential,
which was previously reported in LSCOX by our group [35] and others
[36]. Other signal towards OXPHOS upregulation might be the in-
creased turnover of unassembled proteins by mitochondrial prote-
ases [37] or the related increased level of mitochondrial autophagy.
The comparison of Western blot data and mRNA expression proﬁling
further indicated that posttranscriptional events rather than tran-
scriptional upregulation of genes encoding subunits of these com-
plexes are responsible for the changes observed.
To assess possible changes in gene expression we analyzed the
whole genome expression pattern of LSCOX patient and control
Fig. 3. Digitonin solubilized COX assembly intermediates and COX supercomplexes in LSCOX ﬁbroblasts. Mitochondrial membrane proteins from ﬁbroblasts were solubilized using
4 g detergent/g protein, indicated protein aliquots were resolved by BN-PAGE (patient— P7, 30 μg protein, control— C, 10 μg protein). ForWestern blot detection antibodies to Cox1
(A), Cox4-1 (B), Cox5a (C), Core1 and NDUFA9 (D) were used. COX supercomplexes (SC), high molecular complexes (HMC), monomer (M), assembly intermediates (AI), Cox4-5a
heterodimer (X), free Cox5a subunit (Y) and dimer of complex III (cIII2) are marked in blots and distribution proﬁles (detected signals in patient blots were re-counted to 10 μg
protein). The presence of COX subunits in different COX forms as percentage is illustrated by tables inserted under the proﬁles. In gel activity staining of complex IV in control
(C) and LSCOX patient (P9) mitochondria solubilized using digitonin (4 g detergent/g protein) is depicted in part C of the ﬁgure. Active monomer of cIV in control mitochondria
and active cIV in supercomplexes (SC) in both control and LSCOX patient mitochondria were detected after scanning of the gel through blue ﬁlter.
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whether the mutated SURF1 gene caused changes in the expression
of COX and other OXPHOS genes. Clearly, the downregulation of
COX content was not associated with a signiﬁcant and consistent
change of transcripts for COX subunits, parallel to their low content
or accumulation as in case of Cox5a. This may not be surprising
when assuming that the low content of COX primarily results from
a lack of an assembly factor but not from a lack of COX subunits. On
the other hand, we did not ﬁnd a transcriptional correlation with
the compensatory increase of three respiratory chain complexes, the
adaptive change that could result from a transcriptional activation
of structural genes or speciﬁc assembly factors or pro-mitochondrial
regulatory master genes such as PGC1A, NRF1 and TFAM. None of
those appeared to be the case.The current view of the respiratory chain organization in the inner
mitochondrial membrane has undergone a major paradigm shift dur-
ing the last decade. The complexes are no longer considered as single
entities with electron transfer occurring through mobile carriers co-
enzyme Q (CoQ) and cytochrome c, but rather as organized into
respiratory supercomplexes, also known as respirasomes [38]. The
supercomplexes are composed of cI, cIII, and cIV, and it has been re-
cently demonstrated that they even contain cytochrome c and CoQ
and are therefore capable of transferring electrons all the way from
NADH to oxygen [38,39]. The absence of any of the three complexes
inevitably results in disappearance of the supercomplexes [39]. In
this regard, we were interested how would the selective decrease of
cIV in LSCOX ﬁbroblasts inﬂuence the supercomplex pattern. Indeed,
we observed pronounced changes in the association of COX into
Fig. 4. Dodecyl maltoside-solubilized COX forms in LSCOX ﬁbroblasts. Mitochondrial membrane proteins from ﬁbroblasts were solubilized using 2 g detergent/g protein, indicated
protein aliquots were resolved by BN-PAGE (patient — P7, 30 μg protein, control — C, 10 μg protein). For Western blot detection antibodies to Cox1 and Cox4-1 were used. COX in
high molecular complexes (HMC), COX monomer (M) and assembly intermediate (AI) are marked in blots and distribution proﬁles (with re-counting signals representing patient
to 10 μg protein), inserts give their quantiﬁcation in percents. An arrow marks free Cox4-1 subunits in LSCOX patient ﬁbroblasts.
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practically all of the fully assembled COX in LSCOX was found in the
I–III2–IV1 supercomplex. In controls, the COX was distributed among
the I–III2–IV1–3 supercomplexes, but also a signiﬁcant portion of the
enzyme remained in the form of monomer, dimer and smaller com-
plexes. In control cells, the formation of supercomplexes seemed to
be limited by the cI availability as its whole portion was associated
in supercomplexes. The unassociated portion of COX perhaps repre-
sents the excess enzyme capacity often reported for this complex
[40,41]. In LSCOX cells, on the other hand, the limiting component
was COX, as evidenced by accumulation of the I–III2 supercomplex
or even free cIII2. Our results suggest that upon its assembly into
the holoenzyme, COX was preferentially associated with cI and cIII
to form supercomplexes, likely to the advantage of improved efﬁcien-
cy of the electron transfer through substrate channeling [38]. We
could speculate whether the changes of COX distribution might lead
to functional alterations in respiratory chain. In our previous studies
concerning LSCOX ﬁbroblasts we reported unexpectedly high oxygen
consumption that was only about 30–50% decreased compared to
controls even though the COX content and activity reached only quar-
ter of control values [10,35]. At the time, we interpreted this ﬁnding
as an upregulated electron transport activity of incomplete COX as-
semblies. Looking at the pattern of COX-containing complexes as
revealed by the present study, an alternative explanation comes to
mind. If we assume that only the portion of COX associated in super-
complexes participates in electron transfer from substrates to oxygen,
then this would explain the higher oxygen consumption per unit of
COX in LSCOX ﬁbroblasts compared to controls.
Another issue emanating from our BN-PAGE experiments is the
relative underrepresentation of COX dimer and dimer-containing
supercomplexes in LSCOX cells. This is apparently in contrast to a fre-
quent opinion that dimer represents the active form of the complex
[42]. This popular view is mostly based on the fact, that COX has
been repeatedly crystallized in dimeric form [43]. Also, the isolated
COX dimer shows cooperative kinetics in the binding of cytochrome
c [44,45] suggesting a physiological role for the dimer. On the other
hand, the pattern of supercomplexes that are usually present in mul-
tiple forms differing in the number of copies of COX, or indeed the
predominance of the I–III2–IV1 supercomplex in patient cells strongly
suggests that COX is acquired into supercomplexes in monomeric
form and is able to perform its enzymatic activity as such. Neverthe-
less, we also cannot rule out the possibility that COX assembled inthe absence of Surf1 is unable to dimerize. Similarly, HEK293 cells
with subunit Cox5a knockdown presented with COX assembly defect
that also resulted in decreased level of COX dimeric structures [6].
Whether the dimer underrepresentation is a speciﬁc result of an in-
complete event during assembly or a mere consequence of generally
decreased COX cannot be resolved at the moment.
Owing to the relatively low protein size resolution of 1D BN-PAGE,
we employed 2D BN/BN-PAGE to precisely identify the COX complex
that was associated in the supercomplex. In fact, the detection on the
blots from one-dimensional gels using antibodies against subunits
Cox1, Cox4, and Cox5a could not rule out the possibility that just
the COX assembly intermediate is recruited into the supercomplexes.
Indeed, studies dealing with COX assembly suggested, that supercom-
plexes could contain, in addition to COX holoenzyme, also some COX
assembly subcomplexes [6,46]. Even more speciﬁcally, the study by
Lazarou et al. concerning the assembly of COX nuclear-encoded sub-
units clearly showed that unlike controls, SURF1 patient ﬁbroblasts
are able to efﬁciently incorporate all tested subunits into the super-
complex, including the early-assembled subunit Cox4 [7]. However,
our experiments including activity staining in the 1D gel, and the sec-
ond native dimension in the presence of dodecyl maltoside which dis-
sociates the superassemblies revealed disintegration of the
supercomplex into full size cI, cIII, and cIV, demonstrating that pre-
dominantly the fully assembled and active form of COX rather than
its assembly intermediates interact with other OXPHOS complexes.
Nevertheless, the ﬁnding by Lazarou et al. is very intriguing as it indi-
cates a possible mechanism for COX nuclear subunit recycling of the
full-size complex (within the respiratory supercomplex) speciﬁc for
cells lacking Surf1 protein. In this way, it could substitute the role of
a Surf1 protein-containing complex involved in repair/maintenance
of COX as suggested by Reinhold et al. [47].
The precise identity of the major COX subcomplex accumulated in
LSCOX cells is clearly the most puzzling issue of the present study.
While it is generally agreed that cells harboring SURF1 mutations ac-
cumulate the S2 COX assembly intermediate (composed of subunits
1, 4, and 5a) [17,48,49], several lines of evidence suggest that we
may be looking at a different complex. First of all, the size of the
detected subcomplex – 130 kDa – is much larger than the predicted
mass of S2 intermediate of 85 kDa. As the mass calculations from
BN-PAGE may be incorrect, we further examined the composition of
this subcomplex in the second dimension using SDS-PAGE and
found that it contained at least subunits Cox1, 2, 4, and 5a.
Fig. 5. Two-dimensional BN/BN-PAGE analysis of COX forms in LSCOX ﬁbroblasts. Digitonin-solubilized (4 g/g protein) mitochondrial proteins from control (40 μg protein) and pa-
tient 7 (60 μg protein) ﬁbroblasts were resolved by BN-PAGE in the ﬁrst dimension. In the second dimension 0.02% dodecyl maltoside (DDM) was used in cathode buffers. COX
supercomplexes (SC), dimer (D), monomer (M) and assembly intermediate (AI) were detected using Cox1 (A) and Cox4-1 (B) antibodies. Arrows mark the putative degradation
products of COX.
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sent in excess over the other two subunits, perhaps by as much as one
order of magnitude. We assume that this ﬁnding can only be
explained by the presence of several comigrating complexes with ap-
proximate size close to 130 kDa. One of them might be a canonical
COX assembly intermediate consisting of subunits 1, 2, 4, and 5a in
stoichiometric amount. In addition, Cox1 would be associated in dif-
ferent types of complex(es) lacking any other COX subunit. These as-
semblies could represent not yet described complexes that could
function in maturation of the subunit, insertion of its prosthetic
groups, its posttranslational import into the inner membrane, or
even repair/maintenance of the complex. The precise assignment of
the identity/function of this intermediate would be greatly alleviated
if we knew the function of Surf1. The studies performed in bacteria
suggest that Surf1 serves as a heme-binding chaperone for heme a3
insertion into the Cox1 subunit [50,51]. In the eukaryotic yeast
model, Surf1 ortholog Shy1 is associated within a COX proteinassembly complex of ~450 kDa along with early-assembled subunits
and other assembly factors such as Coa1, Coa3, Cox14, where it func-
tions as a factor coupling Cox1 translational regulation to assembly by
relieving the sequestered Cox1 translational activator Mss51
[46,52–54]. In addition, Shy1 is probably also involved in Cox1 matu-
ration–insertion of heme cofactors similar to bacteria [55,56]. Impor-
tantly, the multiple roles seem to be retained in the mammalian
(human) Surf1, as the protein was found to associate in three distinct
complexes in HEK293 cells [47]. The authors demonstrate that one of
these complexes, of an approximate size of 200 kDa, represents a
bona ﬁde COX assembly intermediate as its formation is dependent
onmitochondrial translation.We can thereforehypothesize, that the ac-
cumulatedCOX subcomplexes in LSCOXﬁbroblasts likely represent the en-
tity identical to the Surf1-containing complex identiﬁed by Reinhold et al.,
of course smaller by 30 kDa due to Suf1 absence. The smaller portion of
the broad ~85–140 kDa band, with dominant Cox1 signal in relation to
other subunits,would represent associations involved in Cox1maturation
Fig. 6. Two-dimensional BN/SDS-PAGE analysis of COX forms in LSCOX ﬁbroblasts. For 2D analysis digitonin-solubilized (4 g/g protein) mitochondrial proteins from control and pa-
tient 7 ﬁbroblasts (50 μg protein aliquots) (A) and DDM solubilized (2 g/g protein) mitochondrial proteins from control and patient 7 ﬁbroblasts (50 μg and 70 μg protein aliquots)
(C) were used. Cox subunits 1, 2, 4-1 and 5a were detected after Western blotting with speciﬁc antibodies. Signals of these subunits in COX supercomplexes (SC), dimer (D), mono-
mer (M), assembly intermediates (AIs, S2, S3), Cox4-5a heterodimer (x), free Cox2 (v), free Cox5a (y) and free Cox4-1 (z) subunits are marked. Differences between separation/
migration of COX assembly intermediates after solubilization of membranes with digitonin (B) and DDM (D) in LSCOX patients are depicted in more detail.
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cruit from a group of proteins fulﬁlling roles similar to yeast proteins
Mss51, Coa1, Coa2, Coa3, or Cox14. Although mammalian orthologs of
these were not identiﬁed, phylogenetically unrelated proteins may have
taken up the vacant niche, such as the recently identiﬁed factor
C12orf62 that links Cox1 translation and assembly [57]. The larger portion
of the accumulated subcomplex, on the other hand, would represent COX
assembly intermediate identiﬁed as S2, likely stalled in the phase of Cox2
association with the Cox1–Cox4–Cox5a complex, as all of these subunits
were found comigrating in this region. Further understanding could be
achieved by mass-spectroscopic analysis of the accumulated subcom-
plexes, and pulse-chase labeling experiments should indicate the position
of these intermediates within the time frame of COX assembly.
Acknowledgements
This work was supported by grants from the Grant Agency of the
Ministry of Health of the Czech Republic (NS9759, NT12370-5), the
Grant Agency of the Czech Republic (305/08/H037), and institutional
support provided by Ministry of Education, Youth and Sports of the
Czech Republic (projects AVOZ 50110509, RVO: 67985823, and
MSM0021620806).
References
[1] B. Beauvoit, O. Bunoust, B. Guerin, M. Rigoulet, ATP-regulation of cytochrome ox-
idase in yeast mitochondria: role of subunit VIa, Eur. J. Biochem. 263 (1999)
118–127.
[2] L.A. Allen, X.J. Zhao, W. Caughey, R.O. Poyton, Isoforms of yeast cytochrome c ox-
idase subunit V affect the binuclear reaction center and alter the kinetics of inter-
action with the isoforms of yeast cytochrome c, J. Biol. Chem. 270 (1995)
110–118.
[3] L.G. Nijtmans, J.W. Taanman, A.O. Muijsers, D. Speijer, C. Van den Bogert, Assem-
bly of cytochrome-c oxidase in cultured human cells, Eur. J. Biochem. 254 (1998)
389–394.[4] V. Tiranti, C. Galimberti, L. Nijtmans, S. Bovolenta, M.P. Perini, M. Zeviani, Charac-
terization of SURF-1 expression and Surf-1p function in normal and disease con-
ditions, Hum. Mol. Genet. 8 (1999) 2533–2540.
[5] L. Stiburek, H. Hansikova, M. Tesarova, L. Cerna, J. Zeman, Biogenesis of eukaryotic
cytochrome c oxidase, Physiol. Res. 55 (Suppl. 2) (2006) S27–S41.
[6] D. Fornuskova, L. Stiburek, L. Wenchich, K. Vinsova, H. Hansikova, J. Zeman, Novel
insights into the assembly and function of human nuclear-encoded cytochrome c
oxidase subunits 4, 5a, 6a, 7a and 7b, Biochem. J. 428 (2010) 363–374.
[7] M. Lazarou, S.M. Smith, D.R. Thorburn, M.T. Ryan, M. McKenzie, Assembly of nu-
clear DNA-encoded subunits into mitochondrial complex IV, and their preferen-
tial integration into supercomplex forms in patient mitochondria, FEBS J. 276
(2009) 6701–6713.
[8] M. Lazarou, M. McKenzie, A. Ohtake, D.R. Thorburn, M.T. Ryan, Analysis of the as-
sembly proﬁles for mitochondrial- and nuclear-DNA-encoded subunits into com-
plex I, Mol. Cell. Biol. 27 (2007) 4228–4237.
[9] J. Yao, E.A. Shoubridge, Expression and functional analysis of SURF1 in Leigh syn-
drome patients with cytochrome c oxidase deﬁciency, Hum. Mol. Genet. 8 (1999)
2541–2549.
[10] P. Pecina, H. Houstkova, H. Hansikova, J. Zeman, J. Houstek, Genetic defects of cy-
tochrome c oxidase assembly, Physiol. Res. 53 (Suppl. 1) (2004) S213–S223.
[11] V. Massa, E. Fernandez-Vizarra, S. Alshahwan, E. Bakhsh, P. Goffrini, I. Ferrero, P.
Mereghetti, P. D'Adamo, P. Gasparini, M. Zeviani, Severe infantile encephalomyo-
pathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cyto-
chrome c oxidase, Am. J. Hum. Genet. 82 (2008) 1281–1289.
[12] E.A. Shoubridge, Cytochrome c oxidase deﬁciency, Am. J. Med. Genet. 106 (2001)
46–52.
[13] M.J. Coenen, L.P. van den Heuvel, C. Ugalde, M. Ten Brinke, L.G. Nijtmans, F.J.
Trijbels, S. Beblo, E.M. Maier, A.C. Muntau, J.A. Smeitink, Cytochrome c oxidase
biogenesis in a patient with a mutation in COX10 gene, Ann. Neurol. 56 (2004)
560–564.
[14] M. Bugiani, V. Tiranti, L. Farina, G. Uziel, M. Zeviani, Novel mutations in COX15 in
a long surviving Leigh syndrome patient with cytochrome c oxidase deﬁciency, J.
Med. Genet. 42 (2005) e28.
[15] D. Leigh, Subacute necrotizing encephalomyelopathy in an infant, J. Neurol. Neu-
rosurg. Psychiatry 14 (1951) 216–221.
[16] M.O. Pequignot, R. Dey, M. Zeviani, V. Tiranti, C. Godinot, A. Poyau, C. Sue, S. Di
Mauro, M. Abitbol, C. Marsac, Mutations in the SURF1 gene associated with
Leigh syndrome and cytochrome c oxidase deﬁciency, Hum. Mutat. 17 (2001)
374–381.
[17] V. Tiranti, K. Hoertnagel, R. Carrozzo, C. Galimberti, M. Munaro, M. Granatiero, L.
Zelante, P. Gasparini, R. Marzella, M. Rocchi, M.P. Bayona-Bafaluy, J.A. Enriquez, G.
Uziel, E. Bertini, C. Dionisi-Vici, B. Franco, T. Meitinger, M. Zeviani, Mutations of
SURF-1 in Leigh disease associated with cytochrome c oxidase deﬁciency, Am. J.
Hum. Genet. 63 (1998) 1609–1621.
1124 N. Kovářová et al. / Biochimica et Biophysica Acta 1822 (2012) 1114–1124[18] Z. Zhu, J. Yao, T. Johns, K. Fu, I. De Bie, C. Macmillan, A.P. Cuthbert, R.F. Newbold, J.
Wang, M. Chevrette, G.K. Brown, R.M. Brown, E.A. Shoubridge, SURF1, encoding a
factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh
syndrome, Nat. Genet. 20 (1998) 337–343.
[19] J. Smeitink, L. van den Heuvel, S. DiMauro, The genetics and pathology of oxida-
tive phosphorylation, Nat. Rev. Genet. 2 (2001) 342–352.
[20] D. Piekutowska-Abramczuk,M.Magner, E. Popowska, M. Pronicki, E. Karczmarewicz, J.
Sykut-Cegielska, T. Kmiec, E. Jurkiewicz, T. Szymanska-Debinska, L. Bielecka, M.
Krajewska-Walasek, K. Vesela, J. Zeman, E. Pronicka, SURF1 missense mutations pro-
mote a mild Leigh phenotype, Clin. Genet. 76 (2009) 195–204.
[21] P. Pecina, M. Capkova, S.K. Chowdhury, Z. Drahota, A. Dubot, A. Vojtiskova, H.
Hansikova, H. Houst'kova, J. Zeman, C. Godinot, J. Houstek, Functional alteration
of cytochrome c oxidase by SURF1 mutations in Leigh syndrome, Biochim. Bio-
phys. Acta 1639 (2003) 53–63.
[22] H.A. Bentlage, U. Wendel, H. Schagger, H.J. ter Laak, A.J. Janssen, J.M. Trijbels, Le-
thal infantile mitochondrial disease with isolated complex I deﬁciency in ﬁbro-
blasts but with combined complex I and IV deﬁciencies in muscle, Neurology 47
(1996) 243–248.
[23] I. Wittig, H.P. Braun, H. Schagger, Blue native PAGE, Nat. Protoc. 1 (2006) 418–428.
[24] I. Wittig, M. Karas, H. Schagger, High resolution clear native electrophoresis for
in-gel functional assays and ﬂuorescence studies of membrane protein com-
plexes, Mol. Cell. Proteomics 6 (2007) 1215–1225.
[25] H. Schagger, G. von Jagow, Tricine-sodium dodecyl sulfate-polyacrylamide gel
electrophoresis for the separation of proteins in the range from 1 to 100 kDa,
Anal. Biochem. 166 (1987) 368–379.
[26] A. Dubot, C. Godinot, V. Dumur, B. Sablonniere, T. Stojkovic, J.M. Cuisset, A.
Vojtiskova, P. Pecina, P. Jesina, J. Houstek, GUG is an efﬁcient initiation codon to
translate the human mitochondrial ATP6 gene, Biochem. Biophys. Res. Commun.
313 (2004) 687–693.
[27] T. Honzik, Z. Drahota, M. Bohm, P. Jesina, T. Mracek, J. Paul, J. Zeman, J. Houstek,
Speciﬁc properties of heavy fraction of mitochondria from human-term placenta
— glycerophosphate-dependent hydrogen peroxide production, Placenta 27
(2006) 348–356.
[28] E. Zerbetto, L. Vergani, F. Dabbeni-Sala, Quantiﬁcation of muscle mitochondrial
oxidative phosphorylation enzymes via histochemical staining of blue native
polyacrylamide gels, Electrophoresis 18 (1997) 2059–2064.
[29] A. Brazma, P. Hingamp, J. Quackenbush, G. Sherlock, P. Spellman, C. Stoeckert, J.
Aach, W. Ansorge, C.A. Ball, H.C. Causton, T. Gaasterland, P. Glenisson, F.C.
Holstege, I.F. Kim, V. Markowitz, J.C. Matese, H. Parkinson, A. Robinson, U.
Sarkans, S. Schulze-Kremer, J. Stewart, R. Taylor, J. Vilo, M. Vingron, Minimum in-
formation about a microarray experiment (MIAME)-toward standards for micro-
array data, Nat. Genet. 29 (2001) 365–371.
[30] G.K. Smyth, Limma: linear models for microarray data, Bioinformatics and Com-
putational Biology Solutions using R and Bioconductor, Springer, New York,
2005, pp. 397–420.
[31] Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: a practical and
powerful approach to multiple testing, J. R. Stat. Soc. (1995) 289–300.
[32] A. Cizkova, V. Stranecky, R. Ivanek, H. Hartmannova, L. Noskova, L. Piherova, M.
Tesarova, H. Hansikova, T. Honzik, J. Zeman, P. Divina, A. Potocka, J. Paul, W.
Sperl, J.A. Mayr, S. Seneca, J. Houstek, S. Kmoch, Development of a human mito-
chondrial oligonucleotide microarray (h-MitoArray) and gene expression analy-
sis of ﬁbroblast cell lines from 13 patients with isolated F1Fo ATP synthase
deﬁciency, BMC Genomics 9 (2008) 38.
[33] F. Sasarman, G. Karpati, E.A. Shoubridge, Nuclear genetic control of mitochondrial
translation in skeletal muscle revealed in patients with mitochondrial myopathy,
Hum. Mol. Genet. 11 (2002) 1669–1681.
[34] M. Sebastiani, C. Giordano, C. Nediani, C. Travaglini, E. Borchi, M. Zani, M. Feccia,
M. Mancini, V. Petrozza, A. Cossarizza, P. Gallo, R.W. Taylor, G. d'Amati, Induction
of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial car-
diomyopathies, J. Am. Coll. Cardiol. 50 (2007) 1362–1369.
[35] P. Pecina, M. Capkova, S.K. Chowdhury, Z. Drahota, A. Dubot, A. Vojtiskova, H.
Hansikova, H. Houst'kova, J. Zeman, C. Godinot, J. Houstek, Functional alteration
of cytochrome c oxidase by SURF1 mutations in Leigh syndrome, Biochim. Bio-
phys. Acta 1639 (2003) 53–63.[36] M. Wasniewska, E. Karczmarewicz, M. Pronicki, D. Piekutowska-Abramczuk, K.
Zablocki, E. Popowska, E. Pronicka, J. Duszynski, Abnormal calcium homeostasis
in ﬁbroblasts from patients with Leigh disease, Biochem. Biophys. Res. Commun.
283 (2001) 687–693.
[37] L. Stiburek, J. Zeman, Assembly factors and ATP-dependent proteases in cyto-
chrome c oxidase biogenesis, Biochim. Biophys. Acta 1797 (2010) 1149–1158.
[38] G. Lenaz, M.L. Genova, Structural and functional organization of the mitochondri-
al respiratory chain: a dynamic super-assembly, Int. J. Biochem. Cell Biol. 41
(2009) 1750–1772.
[39] R. Acin-Perez, P. Fernandez-Silva, M.L. Peleato, A. Perez-Martos, J.A. Enriquez, Re-
spiratory active mitochondrial supercomplexes, Mol. Cell 32 (2008) 529–539.
[40] E. Gnaiger, Oxygen conformance of cellular respiration. A perspective of mito-
chondrial physiology, Adv. Exp. Med. Biol. 543 (2003) 39–55.
[41] A. Kudin, S. Vielhaber, C.E. Elger, W.S. Kunz, Differences in ﬂux control and re-
serve capacity of cytochrome c oxidase (COX) in human skeletal muscle and
brain suggest different metabolic effects of mild COX deﬁciencies, Mol. Biol.
Rep. 29 (2002) 89–92.
[42] F. Fontanesi, I.C. Soto, D. Horn, A. Barrientos, Assembly of mitochondrial cyto-
chrome c-oxidase, a complicated and highly regulated cellular process, Am. J.
Physiol. Cell Physiol. 291 (2006) C1129–C1147.
[43] T. Tsukihara, H. Aoyama, E. Yamashita, T. Tomizaki, H. Yamaguchi, K. Shinzawa-
Itoh, R. Nakashima, R. Yaono, S. Yoshikawa, The whole structure of the 13-
subunit oxidized cytochrome c oxidase at 2.8 A [see comments], Science 272
(1996) 1136–1144.
[44] S. Arnold, B. Kadenbach, The intramitochondrial ATP/ADP-ratio controls cyto-
chrome c oxidase activity allosterically, FEBS Lett. 443 (1999) 105–108.
[45] I. Lee, A.R. Salomon, S. Ficarro, I. Mathes, F. Lottspeich, L.I. Grossman, M.
Huttemann, cAMP-dependent tyrosine phosphorylation of subunit I inhibits cyto-
chrome c oxidase activity, J. Biol. Chem. 280 (2005) 6094–6100.
[46] D.U. Mick, K. Wagner, M. van der Laan, A.E. Frazier, I. Perschil, M. Pawlas, H.E.
Meyer, B. Warscheid, P. Rehling, Shy1 couples Cox1 translational regulation to cy-
tochrome c oxidase assembly, EMBO J. 26 (2007) 4347–4358.
[47] R. Reinhold, B. Bareth, M. Balleininger, M. Wissel, P. Rehling, D.U. Mick, Mimicking
a SURF1 allele reveals uncoupling of cytochrome c oxidase assembly from trans-
lational regulation in yeast, Hum. Mol. Genet. 20 (2011) 2379–2393.
[48] L. Stiburek, K. Vesela, H. Hansikova, P. Pecina, M. Tesarova, L. Cerna, J. Houstek, J.
Zeman, Tissue-speciﬁc cytochrome c oxidase assembly defects due to mutations
in SCO2 and SURF1, Biochem. J. 392 (2005) 625–632.
[49] J.W. Taanman, S.L. Williams, Assembly of cytochrome c oxidase: what can we
learn from patients with cytochrome c oxidase deﬁciency? Biochem. Soc. Trans.
29 (2001) 446–451.
[50] A. Hannappel, F.A. Bundschuh, B. Ludwig, Characterization of heme-binding prop-
erties of Paracoccus denitriﬁcans Surf1 proteins, FEBS J. 278 (2011) 1769–1778.
[51] F.A. Bundschuh, A. Hannappel, O. Anderka, B. Ludwig, Surf1, associated with Leigh
syndrome in humans, is a heme-binding protein in bacterial oxidase biogenesis, J.
Biol. Chem. 284 (2009) 25735–25741.
[52] A. Barrientos, D. Korr, A. Tzagoloff, Shy1p is necessary for full expression of mito-
chondrial COX1 in the yeast model of Leigh's syndrome, EMBO J. 21 (2002) 43–52.
[53] A. Barrientos, A. Zambrano, A. Tzagoloff, Mss51p and Cox14p jointly regulate mi-
tochondrial Cox1p expression in Saccharomyces cerevisiae, EMBO J. 23 (2004)
3472–3482.
[54] I.C. Soto, F. Fontanesi, J. Liu, A. Barrientos, Biogenesis and assembly of eukaryotic
cytochrome c oxidase catalytic core, Biochim. Biophys. Acta (2011), doi:
10.1016/j.bbabio.2011.09.005.
[55] O. Khalimonchuk, M. Bestwick, B. Meunier, T.C. Watts, D.R. Winge, Formation of
the redox cofactor centers during Cox1 maturation in yeast cytochrome oxidase,
Mol. Cell. Biol. 30 (2010) 1004–1017.
[56] F. Pierrel, M.L. Bestwick, P.A. Cobine, O. Khalimonchuk, J.A. Cricco, D.R. Winge,
Coa1 links the Mss51 post-translational function to Cox1 cofactor insertion in cy-
tochrome c oxidase assembly, EMBO J. 26 (2007) 4335–4346.
[57] W. Weraarpachai, F. Sasarman, T. Nishimura, H. Antonicka, K. Aure, A. Rotig, A.
Lombes, E.A. Shoubridge, Mutations in C12orf62, a factor that couples COX I syn-
thesis with cytochrome c oxidase assembly, cause fatal neonatal lactic acidosis,
Am. J. Hum. Genet. 90 (2012) 142–151.
